For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

Novo Holdings, a leading life science investor, today announced that it has invested in a $200M Series A launch financing for Windward ...

Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is needed to improve holistic patient care, according to a new editorial.

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...

The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.